Journal of Clinical Pharmacology

Papers
(The H4-Index of Journal of Clinical Pharmacology is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
71
44
Protecting Mothers and Babies Through Research41
Incidence of Antiseizure Medication–Induced Severe Cutaneous Adverse Reactions in Malaysia32
Assessment of the Effect of Organ Impairment on the Pharmacokinetics of 2′‐MOE and Phosphorothioate Modified Antisense Oligonucleotides31
Methoxyethyl Etomidate Hydrochloride (ET‐26): A Phase I Clinical Trial Assessing Drug–Drug Interactions in Healthy Subjects29
Maternal–Fetal Drug Development: An Industry Perspective27
Clinical Lactation Studies of Neuropsychiatric Medications: Clinical Pharmacology and Labeling Considerations26
Vancomycin Associated Purpuric Symmetrical Drug‐Related Intertriginous and Flexural Exanthema: A Rare Association and an Uncommon Presentation24
What Is the Role of Sex‐Related Differences in the Effectiveness and Safety of Biological Drugs Used in Patients With Severe Asthma?23
Issue Information23
21
Challenges in Conducting Therapeutic Trials in Pregnancy: Emphasizing Recent Lessons Learned21
Association Between the Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Drug‐Induced Acute Kidney Injury: Analysis of 2 Databases20
In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug Transporters20
Influence of Renal Function on Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Romosozumab19
Development and Verification of a Japanese Pediatric Physiologically Based Pharmacokinetic Model with Emphasis on Drugs Eliminated by Cytochrome P450 or Renal Excretion18
Efanesoctocog Alfa Population Pharmacokinetics and Repeated Time‐To‐Event Analysis of Bleeds in Adults, Adolescents, and Children with Severe Hemophilia A18
Pharmacokinetics and Safety of a Novel Extended‐Release Microsphere Formulation of Risperidone in Patients with Schizophrenia or Schizoaffective Disorder18
0.05886697769165